BI’s Ofev Approved for Group of Lung Diseases

The FDA has given the go-ahead for Boehringer Ingelheim’s Ofev (nintedanib) for treating patients with chronic fibrosing interstitial lung diseases (ILD) with a progressive trait.

Chronic fibrosing ILD spans a group of fibrotic lung diseases caused by a range of autoimmune and other conditions. Patients can experience lung scarring and rapid progression of the disease.

Ofev was previously approved to treat idiopathic pulmonary fibrosis and to slow the rate of decline in pulmonary function among patients with ILD associated with systemic sclerosis or scleroderma.